KRN125(pegfilgrastim), PLR001(plerixafor)

Phase 2

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Multiple Myeloma and Malignant Lymphoma

Drug Information

Target Indication

Multiple Myeloma and Malignant Lymphoma

Clinical Trial

Last updated: 12/11/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

4151.T

Kyowa Kirin Co., Ltd.

Related Pipeline

Moderate to Severe Systemic Sclerosis

Parathyroid Carcinoma

Secondary Hyperparathyroidism

Parkinson's Disease

Psoriasis Vulgaris